Cognitive impairment in patients with Parkinson's disease: Diagnosis, biomarkers, and treatment

The Lancet Neurology

Volumn 11, Issue 8, 2012, Pages 697-707

  Svenningsson, Per ^a   Westman, Eric ^b   Ballard, Clive ^c   Aarsland, Dag ^b,d,e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d STAVANGER UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMANTADINE; AMYLOID; APOLIPOPROTEIN E; ATOMOXETINE; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; CLOZAPINE; DONEPEZIL; GALANTAMINE; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; MAPT PROTEIN; MEMANTINE; NORTRIPTYLINE; PERGOLIDE; PRAMIPEXOLE; RIVASTIGMINE; SNCA PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; COGNITION; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TOLERABILITY; GENETIC POLYMORPHISM; HUMAN; INCIDENCE; LEWY BODY; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NEUROPATHOLOGY; NEUROPHYSIOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW;

ALPHA-SYNUCLEIN; BIOLOGICAL MARKERS; BRAIN; COGNITION DISORDERS; DISEASE PROGRESSION; HUMANS; PARKINSON DISEASE;

EID: 84863880556     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(12)70152-7     Document Type: Review

References (132)

1. Winter Y, von Campenhausen S, Arend M, et al. Health-related quality of life and its determinants in Parkinson's disease: results of an Italian cohort study. Parkinsonism Relat Disord 2011, 17:265-269.
2. Vossius C, Larsen JP, Janvin C, Aarsland D The economic impact of cognitive impairment in Parkinson's disease. Mov Disord 2011, 26:1541-1544.
3. Fletcher P, Leake A, Marion MH Patients with Parkinson's disease dementia stay in the hospital twice as long as those without dementia. Mov Disord 2011, 26:919.
4. Hu M, Cooper J, Beamish R, et al. How well do we recognise non-motor symptoms in a British Parkinson's disease population?. J Neurol 2011, 258:1513-1517.
5. Aarsland D, Zaccai J, Brayne C A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005, 20:1255-1263.
6. Riedel O, Klotsche J, Spottke A, et al. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease. J Neurol 2010, 257:1073-1082.
7. Willis AW, Schootman M, Kung N, Evanoff BA, Perlmutter JS, Racette BA Predictors of survival in patients with Parkinson disease. Arch Neurol 2012, 69:601-607.
8. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sørensen P Risk of dementia in Parkinson's disease-a community-based, prospective study. Neurology 2001, 56:730-736.
9. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003, 60:387-392.
10. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008, 23:837-844.
11. Evans JR, Mason SL, Williams-Gray CH, et al. The natural history of treated Parkinson's disease in an incident, community based cohort. J Neurology Neurosurg Psychiatry 2011, 82:1112-1118.
12. Aarsland D, Kvaloy JT, Andersen K, et al. The effect of age of onset of PD on risk of dementia. J Neurol 2007, 254:38-45.
13. Aarsland D, Andersen K, Larsen JP, et al. The rate of cognitive decline in Parkinson disease. Arch Neurol 2004, 61:1906-1911.
14. Aarsland D, Muniz G, Matthews F Nonlinear decline of mini-mental state examination in Parkinson's disease. Mov Disord 2011, 26:334-337.
15. Johnson DK, Galvin JE Longitudinal changes in cognition in Parkinson's disease with and without dementia. Dement Geriatr Cogn Disord 2011, 31:98-108.
16. Kempster PA, O'Sullivan SS, Holton JL, Revesz T, Lees AJ Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain 2010, 133:1755-1762.
17. van Rooden SM, Colas F, Martinez-Martin P, et al. Clinical subtypes of Parkinson's disease. Mov Disord 2011, 26:51-58.
18. Halliday GM, McCann H The progression of pathology in Parkinson's disease. Ann N Y Acad Sci 2010, 1184:188-195.
19. Boot BP, Boeve BF, Roberts RO, et al. Probable rapid eye movement sleep behavior disorder increases risk for mild cognitive impairment and Parkinson disease: a population-based study. Ann Neurol 2012, 71:49-56.
20. Postuma RB, Bertrand JA, Montplaisir J, et al. Rapid eye movement sleep behavior disorder and risk of dementia in Parkinson's disease: a prospective study. Mov Disord 2012, 27:617-626.
21. Baba T, Kikuchi A, Hirayama K, et al. Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson's disease: a 3 year longitudinal study. Brain 2012, 135:161-169.
22. Litvan I, Aarsland D, Adler CH, et al. MDS task force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord 2011, 26:1814-1824.
23. Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010, 75:1062-1069.
24. Aarsland D, Bronnick K, Larsen JP, Tysnes OB, Alves G Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009, 72:1121-1126.
25. Dalrymple-Alford JC, Livingston L, MacAskill MR, et al. Characterizing mild cognitive impairment in Parkinson's disease. Mov Disord 2011, 26:629-636.
26. Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society task force guidelines. Mov Disord 2012, 27:349-356.
27. Rosenthal E, Brennan L, Xie S, et al. Association between cognition and function in patients with Parkinson disease with and without dementia. Mov Disord 2010, 25:1170-1176.
28. Janvin CC, Larsen JP, Aarsland D, Hugdahl K Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006, 21:1343-1349.
29. Kehagia AA, Barker RA, Robbins TW Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 2010, 9:1200-1213.
30. Bronnick K, Alves G, Aarsland D, Tysnes OB, Larsen JP Verbal memory in drug-naive, newly diagnosed Parkinson's disease. The retrieval deficit hypothesis revisited. Neuropsychology 2011, 25:114-124.
31. Salmon DP, Galasko D, Hansen LA, et al. Neuropsychological deficits associated with diffuse Lewy body disease. Brain Cogn 1996, 31:148-165.
32. Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009, 132:2958-2969.
33. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000, 54:1916-1921.
34. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 2005, 58:773-776.
35. Braak H, Rub U, Jansen Steur ENH, Del Tredici K, de Vos RAI. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology; 64: 1404-10.
36. Sabbagh MN, Adler CH, Lahti TJ, et al. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord 2009, 23:295-297.
37. Jellinger KA, Attems J Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol 2008, 115:427-436.
38. Ballard C, Ziabreva I, Perry R, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 2006, 67:1931-1934.
39. Compta Y, Parkkinen L, O'Sullivan SS, et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. Brain 2011, 134:1493-1505.
40. Kurz MW, Schlitter AM, Larsen JP, Ballard C, Aarsland D Familial occurrence of dementia and parkinsonism: a systematic review. Dement Geriatr Cogn Disord 2006, 22:288-295.
41. Setó-Salvia N, Clarimon J, Pagonabarraga J, et al. Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. Arch Neurol 2011, 68:359-364.
42. Goris A, Williams-Gray CH, Clark GR, et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol 2007, 62:145-153.
43. Jones EL, Aarsland D, Londos E, Ballard C A pilot study examining associations between DYRK1A and alpha-synuclein dementias. Neurodegen Dis 2012, 10:229-231.
44. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009, 361:1651-1661.
45. Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009, 132:1783-1794.
46. Alcalay RN, Caccappolo E, Mejia-Santana H, et al. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology 2012, 78:1434-1440.
47. Setó-Salvia N, Pagonabarraga J, Houlden H, et al. Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course. Mov Disord 2012, 27:393-399.
48. Alcalay RN, Mejia-Santana H, Tang MX, et al. Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease. J Clin Exp Neuropsychol 2010, 32:775-779.
49. Guerini FR, Beghi E, Riboldazzi G, et al. BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson's disease. Eur J Neurology 2009, 16:1240-1245.
50. Williams-Gray CH, Goris A, Saiki M, et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. J Neurology 2009, 256:493-498.
51. Kurz MW, Dekomien G, Nilsen OB, Larsen JP, Aarsland D, Alves G APOE alleles in Parkinson disease and their relationship to cognitive decline: a population-based, longitudinal study. J Geriatr Psychiatry Neurol 2009, 22:166-170.
52. Lane R, He Y, Morris C, Leverenz JB, Emre M, Ballard C BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. Mov Disord 2009, 24:392-400.
53. Morley JF, Xie SX, Hurtig HI, et al. Genetic influences on cognitive decline in Parkinson's disease. Mov Disord 2012, 27:512-518.
54. Klassen BT, Hentz JG, Shill HA, et al. Quantitative EEG as a predictive biomarker for Parkinson disease dementia. Neurol 2011, 77:118-124.
55. Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurol 2010, 75:1055-1061.
56. Chen-Plotkin AS, Hu WT, Siderowf A, et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol 2011, 69:655-663.
57. Weintraub D, Dietz N, Duda JE, et al. Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. Brain 2012, 135:170-180.
58. Dujardin K, Defebvre L, Duhamel A, et al. Cognitive and SPECT characteristics predict progression of Parkinson's disease in newly diagnosed patients. J Neurol 2004, 251:1383-1392.
59. Bohnen NI, Koeppe RA, Minoshima S, et al. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med 2011, 52:848-855.
60. Burton EJ, McKeith IG, Burn DJ, Williams ED, O'Brien JT Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 2004, 127:791-800.
61. Kenny ER, Burton EJ, O'Brien JT A volumetric magnetic resonance imaging study of entorhinal cortex volume in dementia with lewy bodies: a comparison with Alzheimer's disease and Parkinson's disease with and without dementia. Dement Geriatr Cogn Disord 2008, 26:218-225.
62. Lyoo CH, Ryu YH, Lee MS Topographical distribution of cerebral cortical thinning in patients with mild Parkinson's disease without dementia. Mov Disord 2010, 25:496-499.
63. Song SK, Lee JE, Park H-J, Sohn YH, Lee JD, Lee PH The pattern of cortical atrophy in patients with Parkinson's disease according to cognitive status. Mov Disord 2011, 26:289-296.
64. Weintraub D, Doshi J, Koka D, et al. Neurodegeneration across stages of cognitive decline in Parkinson disease. Arch Neurol 2011, 68:1562-1568.
65. Beyer MK, Janvin CC, Larsen JP, Aarsland D A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry 2007, 78:254-259.
66. Apostolova LG, Beyer M, Green AE, et al. Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia. Mov Disord 2010, 25:687-695.
67. Dalaker TO, Zivadinov R, Ramasamy DP, et al. Ventricular enlargement and mild cognitive impairment in early Parkinson's disease. Mov Disord 2011, 26:297-301.
68. Jokinen P, Scheinin N, Aalto S, et al. [11C]PIB-, [18F]FDG-PET and MRI imaging in patients with Parkinsons disease with and without dementia. Parkinsonism Relat Disord 2010, 16:666-670.
69. Burton EJ, McKeith IG, Burn DJ, O'Brien JT Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging. Mov Disord 2005, 20:1571-1576.
70. Westman E, Simmons A, Zhang Y, et al. Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and healthy controls. Neuroimage 2011, 54:1178-1187.
71. Bohnen NI, Albin RL White matter lesions in Parkinson disease. Nat Rev Neurol 2011, 7:229-236.
72. Lee SJ, Kim JS, Yoo JY, et al. Influence of white matter hyperintensities on the cognition of patients with Parkinson disease. Alzheimer Dis Assoc Disord 2010, 24:227-233.
73. Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 2008, 70:1470-1477.
74. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003, 60:1745-1748.
75. Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008, 79:1331-1338.
76. Firbank MJ, Colloby SJ, Burn DJ, McKeith IG, O'Brien JT Regional cerebral blood flow in Parkinson's disease with and without dementia. Neuroimage 2003, 20:1309-1319.
77. Nobili F, Abbruzzese G, Morbelli S, et al. Amnestic mild cognitive impairment in Parkinson's disease: a brain perfusion SPECT study. Mov Disord 2009, 24:414-421.
78. Müller U, Wächter T, Barthel H, Reuter M, von Cramon DY Striatal [123I]beta-CIT SPECT and prefrontal cognitive functions in Parkinson's disease. J Neural Transm 2000, 107:303-319.
79. Beyer MK, Aarsland D Grey matter atrophy in early versus late dementia in Parkinson's disease. Parkinsonism Relat Disord 2008, 14:620-625.
80. Montine TJ, Shi M, Quinn JF, et al. CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010, 25:2682-2685.
81. Alves G, Bronnick K, Aarsland D, et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2010, 81:1080-1086.
82. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011, 10:230-240.
83. Ballard C, Jones EL, Londos E, Minthon L, Francis P, Aarsland D alpha-Synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies. Int Psychogeriatr 2010, 22:321-327.
84. Tokuda T, Qureshi MM, Ardah MT, et al. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010, 75:1766-1772.
85. Leverenz JB, Watson GS, Shofer J, Zabetian CP, Zhang J, Montine TJ Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. Parkinsonism Relat Disord 2011, 17:61-64.
86. Menza M, Dobkin RD, Marin H, et al. The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease. Psychosomatics 2010, 51:449-474.
87. Westman E, Wahlund LO, Foy C, et al. Combining MRI and MRS to distinguish between Alzheimer's disease and healthy controls. J Alzheimer Dis 2010, 22:171-181.
88. Zhang D, Wang Y, Zhou L, Yuan H, Shen D Multimodal classification of Alzheimer's disease and mild cognitive impairment. Neuroimage 2011, 55:856-867.
89. Vernon AC, Ballard C, Modo M Neuroimaging for Lewy body disease: is the in vivo molecular imaging of α-synuclein neuropathology required and feasible?. Brain Res Rev 2010, 65:28-55.
90. 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007, 6:305-313.
91. O'Brien JT, Colloby S, Fenwick J, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004, 61:919-925.
92. 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Br J Psychiatry 2009, 194:34-39.
93. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007, 22:1689-1707.
94. Dujardin K, Dubois B, Tison F, et al. Parkinson's disease dementia can be easily detected in routine clinical practice. Mov Disord 2010, 25:2769-2776.
95. Kulisevsky J, Pagonabarraga J Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment. Mov Disord 2009, 24:1103-1110.
96. Martinez-Martin P, Falup-Pecurariu C, Rodriguez-Blazquez C, et al. Dementia associated with Parkinson's disease: applying the Movement Disorder Society task force criteria. Parkinsonism Relat Disord 2011, 17:621-624.
97. Klein JC, Eggers C, Kalbe E, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010, 74:885-892.
98. Rolinski M, Fox C, Maidment I, McShane R Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev 2012, 3. CD006504.
99. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004, 351:2509-2518.
100. Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord 2006, 21:456-461.
101. Oertel W, Poewe W, Wolters E, et al. Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia: a retrospective analysis of a double-blind trial and an open-label extension. Drug Safety 2008, 31:79-94.
102. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000, 356:2031-2036.
103. Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006, 21:1899-1907.
104. Barone P, Burn DJ, van Laar T, Hsu C, Poewe W, Lane RM Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. Mov Disord 2008, 23:1532-1540.
105. Wesnes KA, McKeith I, Edgar C, Emre M, Lane R Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 2005, 65:1654-1656.
106. Schmitt FA, Farlow MR, Meng X, Tekin S, Olin JT Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia. CNS Neurosci Ther 2010, 16:330-336.
107. Ceravolo R, Volterrani D, Frosini D, et al. Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia. J Neural Transm 2006, 113:1787-1790.
108. Fogelson N, Kogan E, Korczyn AD, Giladi N, Shabtai H, Neufeld MY Effects of rivastigmine on the quantitative EEG in demented parkinsonian patients. Acta Neurol Scand 2003, 107:252-255.
109. van Laar T, De Deyn PP, Aarsland D, Barone P, Galvin JE Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data. CNS Neurosci Ther 2011, 17:428-441.
110. Dubois B, Tolosa E, Kulisevsky J, et al. Efficacy and safety of donepezil in the treatment of Parkinson's disease patients with dementia. 8th International Conference on Alzheimer's and Parkinson's Diseases; Salzburg, Austria; March 14-18, 2007.
111. Leroi I, Overshott R, Byrne EJ, Daniel E, Burns A Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Mov Disord 2009, 24:1217-1221.
112. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009, 8:613-618.
113. Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010, 9:969-977.
114. Ondo WG, Shinawi L, Davidson A, Lai D Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial. Parkinsonism Relat Disord 2011, 17:156-159.
115. Larsson V, Engedal K, Aarsland D, Wattmo C, Minthon L, Londos E Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson's disease dementia. Dement Geriatr Cogn Disord 2011, 32:227-234.
116. Larsson V, Aarsland D, Ballard C, Minthon L, Londos E The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. Int J Geriatr Psychiatry 2010, 25:1030-1038.
117. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011, 26(suppl 3):S42-S80.
118. Weintraub D, Mavandadi S, Mamikonyan E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 2010, 75:448-455.
119. Cooper JA, Sagar HJ, Doherty SM, Jordan N, Tidswell P, Sullivan EV Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients. Brain 1992, 115:1701-1725.
120. Mattis PJ, Tang CC, Ma Y, Dhawan V, Eidelberg D Network correlates of the cognitive response to levodopa in Parkinson disease. Neurology 2011, 77:858-865.
121. Hanagasi HA, Gurvit H, Unsalan P, et al. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov Disord 2011, 26:1851-1858.
122. Inzelberg R, Bonuccelli U, Schechtman E, et al. Association between amantadine and the onset of dementia in Parkinson's disease. Mov Disord 2006, 21:1375-1379.
123. Bedard MA, Pillon B, Dubois B, Duchesne N, Masson H, Agid Y Acute and long-term administration of anticholinergics in Parkinson's disease: specific effects on the subcortico-frontal syndrome. Brain Cogn 1999, 40:289-313.
124. Parsons TD, Rogers SA, Braaten AJ, Woods SP, Troster AI Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis. Lancet Neurol 2006, 5:578-588.
125. Witt K, Daniels C, Krack P, et al. Negative impact of borderline global cognitive scores on quality of life after subthalamic nucleus stimulation in Parkinson's disease. J Neurol Sci 2011, 310:261-266.
126. Daniels C, Krack P, Volkmann J, et al. Risk factors for executive dysfunction after subthalamic nucleus stimulation in Parkinson's disease. Mov Disord 2010, 25:1583-1589.
127. Hauser RA, Cantillon M, Pourcher E, et al. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol 2011, 10:221-229.
128. Chazot PL Therapeutic potential of histamine H3 receptor antagonists in dementias. Drug News Perspect 2010, 23:99-103.
129. Ballard CG, Chalmers KA, Todd C, et al. Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies. Neurology 2007, 68:1726-1729.
130. Jean L, Bergeron ME, Thivierge S, Simard M Cognitive intervention programs for individuals with mild cognitive impairment: systematic review of the literature. Am J Geriatr Psychiatry 2010, 18:281-296.
131. Backman L, Nyberg L, Soveri A, et al. Effects of working-memory training on striatal dopamine release. Science 2011, 333:718.
132. Paris AP, Saleta HG, de la Cruz Crespo Maraver M, et al. Blind randomized controlled study of the efficacy of cognitive training in Parkinson's disease. Mov Disord 2011, 26:1251-1258.